Form 4: Mira Pharmaceuticals Executive Awarded Stock Options

Matthew Paul Del Giudice, an executive at Mira Pharmaceuticals, was granted 25,000 stock options with a $1.19 exercise price.

Summary

• Matthew Paul Del Giudice of Mira Pharmaceuticals was granted 25,000 stock options.
• The exercise price for these options is $1.19 per share, which was the closing price of the company's stock on December 6, 2024.
• The options were granted on December 6, 2024, under the company's 2022 Omnibus Incentive Plan.
• 50% of the options will vest six months after the grant date, and the remaining 50% will vest one year after the grant date.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally positive for aligning management and shareholder interests. There are no negative aspects to the announcement.

Positives

• The stock options provide an incentive for the executive to contribute to the company's success.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock option grants are a common practice in the pharmaceutical industry to incentivize executives and align their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for executives in the pharmaceutical industry, often used to attract and retain talent.
• The vesting schedule of 50% after six months and 50% after one year is a fairly typical structure for stock option grants.
• The exercise price being set at the closing price on the grant date is also a common practice to ensure the executive benefits from future stock price appreciation.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the executive to increase the company's value.
• The executive benefits from the potential for future gains if the stock price increases.

Key Dates

Keywords

stock options, executive compensation, vesting, Mira Pharmaceuticals, equity incentive